依达拉奉右莰醇联合丁苯酞对急性缺血性脑卒中后轻中度血管性认知障碍的影响

Clinical study of mild to moderate vascular cognitive impairment after acute ischemic stroke induced by edaravonthrorphenol combined with butylphthalide

目的 研究依达拉奉右莰醇联合丁苯酞治疗急性缺血性脑卒中(acute ischemic stroke, AIS)后轻中度血管性认知障碍(vascular cognitive impairment, VCI)的临床效果。方法 选取2021年5月至2022年5月安阳市人民医院神经内科收治的急性缺血性脑卒中患者98例,两组均采用阿替普酶静脉溶栓,同时将以依达拉奉右莰醇单药治疗的48例作为对照组,以依达拉奉右莰醇与丁苯酞联合治疗的50例作为研究组,比较两组疾病疗效、北京版蒙特利尔认知评估量表(Montreal Cognitive Assessment, MoCA)、简易智能状态量表(Mini-mental State Examination, MMSE)评分以及药物不良反应。结果 治疗前两组MMSE与MoCA两项评分比较差异均不明显,P>0.05;治疗后两组各项评分均有提升,且研究组两项评分分别为(26.33±2.41)分与(26.11±2.08)分,均高于对照组,P<0.05;研究组治疗后总有效率98.00%,高于对照组的83.33%,P<0.05;研究组治疗后不良反应总发生率6.00%,与对照组的8.33%比较无统计学意义(P>0.05)。结论 AIS后轻中度血管性认知障碍采用依达拉奉右莰醇联合丁苯酞对恢复患者认知功能效果理想,安全性及临床应用价值均较高。

Objective To study the clinical effects of edaravond-Edorphenol combined with butaphthalide in the treatment of mild and moderate vascular cognitive impairment(VCI) after acute ischemic stroke(AIS). Methods A total of 98 patients with acute ischemic stroke admitted to the Department of Neurology of Anyang People’s Hospital from May 2021 to May 2022 were selected. Both groups received intravenous thrombolytic therapy with alteplase. Meanwhile, 48 patients treated with Edaravonedorcamphenol monotherapy were selected as the control group, and 50 patients treated with Edaravonedorcamphenol combined with butylphthalide were selected as the study group. Disease efficacy, Examinationscores Mini-mental State(MMSE), Cognitive Assessment Montreal(MoCA) scores and adverse drug reactions were compared between the two groups. Results Before treatment, there were no significant differences in MMSE and MoCA scores between the two groups, P>0.05. After treatment, all scores of the two groups were improved, and the two scores of the study group were(26.33±2.41) points and(26.11±2.08) points respectively, which were higher than those of contral groupP<0.05;The group study was 98.00%total of the effective rate, which was that higher than that of control group(83.33%), P<0.05. The total incidence of adverse reactions in the study group was 6.00%, compared with 8.33% in the control group(P>0.05). Conclusions Edaravond-Edorphenol combined with butylphthalide is effective in the treatment of mild and moderate VCI after acute ischemic stroke, which can promote the recovery of cognitive function in patients, and has high safey and clinical application value.